A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

INTRODUCTION: This Phase Ib trial investigated the safety, tolerability, and recommended phase 2 dose for the pan-PI3K/mTOR inhibitor, GSK2126458 (GSK458), and trametinib combination when administered to patients with advanced solid tumors. PATIENTS AND METHODS: Patients with advanced solid tumors r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Grilley-Olson, J. E., Bedard, P. L., Fasolo, A., Cornfeld, M., Cartee, L., Razak, A. R. Abdul, Stayner, L.-A., Wu, Y., Greenwood, R., Singh, R., Lee, C. B., Bendell, J., Burris, H. A., Conte, G. Del, Sessa, C., Infante, J. R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574157/
https://ncbi.nlm.nih.gov/pubmed/27450049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0377-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados